Azienda U.S.L. 1 di Massa e Carrara Report issue

Government Phase 3

Organization Overview

First Clinical Trial
2015
NCT02503319
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Azienda USL1 di Massa e Carrara | Dr.Antonio Franco Ragusa

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Embolism (Phase 3)

Hemorrhage (Phase 3)

Postpartum Hemorrhage (Phase 3)

Pulmonary Embolism (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3